强生
JNJ
255.56
+2.28
+0.90%
强生
US · JNJ
#25 按市值排名
上市于 1970
255.56
+2.28
+0.90%
实时 - 追踪5344个代码 - 心跳于265秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了16家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 76.38% -0.09pp
- 机构数量
- 5,279 -16
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund62.57%
Public Company4.79%
Private Company3.39%
Government Pension Fund2.04%
Sovereign Wealth Fund1.41%
Hedge Fund0.93%
Family Office/Trust0.50%
Insurance Company0.35%
Government0.12%
VC/PE Fund0.14%
Other23.88%
主要股东 截至 2026-06-30
BlackRock
8.80% · 212.10M 股
Vanguard Capital Management, LLC
7.09% · 170.74M 股
State Street Global Advisors
5.55% · 133.78M 股
Vanguard Portfolio Management, LLC
2.67% · 64.37M 股
Geode Capital Management, LLC
2.45% · 59.09M 股
Other
73.44%
J.P. Morgan Asset Management, Inc.
1.86% · 44.73M 股
Norges Bank Investment Management
1.32% · 31.83M 股
State Farm Mutual Automobile Insurance Company
1.31% · 31.59M 股
UBS Asset Management
1.22% · 29.45M 股
Northern Trust Global Investments
1.19% · 28.79M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 27次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Joaquin Duato | Chairperson & CEO | 0.01% |
| Jennifer Taubert | Executive VP & Worldwide Chairman of Pharmaceuticals | 0.01% |
| Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | 0.00% |
| Joseph Wolk | Chief Financial Officer | 0.00% |
| Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 0.00% |
| James Swanson | Executive Vice President | 0.00% |
| John Reed | Executive Vice President of Pharmaceuticals, R&D | 0.00% |
| Robert Decker | Controller & Chief Accounting Officer | 0.00% |
| Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | 0.00% |
| Kristen Mulholland | Head of Human Resources of Global Total Rewards | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +180 | -- |
| 2026-09-07 | Eugene Woods | Director | Other Derivative Acquisition | +135 | -- |
| 2026-09-07 | Daniel Pinto | Director | Other Derivative Acquisition | +113 | -- |
| 2026-09-01 | Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | Derivative Exercise and Sale | -33,597 | $131.94–274.74 |
| 2026-08-31 | Tom Cavanaugh | Company Group Chairman for North America Innovative Medicine | Initial Statement of Beneficial | 0 | -- |
| 2026-08-16 | Jennifer Taubert | Executive VP & Worldwide Chairman of Pharmaceuticals | Derivative Exercise and Sale | -15,000 | $115.67–263.36 |
| 2026-08-12 | Joaquin Duato | Chairperson & CEO | Derivative Exercise and Sale | -123,291 | $115.67–262.00 |
| 2026-08-05 | Elizabeth Forminard | Executive Vice President | Open Market Disposition | -6,574 | $255.93 |
| 2026-08-05 | Elizabeth Forminard | Executive Vice President | Derivative Exercise and Sale | -9,344 | $131.94–257.76 |
| 2026-08-04 | Joaquin Duato | Chairperson & CEO | Open Market Disposition | -48,480 | $258.06–258.74 |
| 2026-07-19 | Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | Derivative Exercise and Sale | -23,054 | $129.51–251.27 |
| 2026-06-10 | Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | Derivative Exercise and Sale | -10,000 | $115.67–241.15 |
| 2026-06-08 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +214 | -- |
| 2026-06-08 | Eugene Woods | Director | Other Derivative Acquisition | +161 | -- |
| 2026-06-08 | Daniel Pinto | Director | Other Derivative Acquisition | +134 | -- |
| 2026-04-30 | John Reed | Executive Vice President of Pharmaceuticals, R&D | Derivative Exercise and Sale | -11,002 | $229.85 |
| 2026-04-30 | John Reed | Executive Vice President of Pharmaceuticals, R&D | Derivative Exercise and Retained | +14,253 | -- |
| 2026-04-22 | John Morikis | Director | Other Derivative Acquisition | +1,540 | -- |
| 2026-04-22 | Hubert Joly | Independent Director | Other Derivative Acquisition | +975 | -- |
| 2026-04-22 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +975 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:31 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
talc litigation headlines still spook this stock every few months but the pharma pipeline keeps quietly delivering. slow and steady, exactly how I like my healthcare names.